Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus AJOVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus AJOVY.
AIMOVIG vs AJOVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
Ajovy (fremanezumab) is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the CGRP receptor, thereby inhibiting CGRP-mediated neurogenic vasodilation and pain transmission in trigeminal sensory neurons.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
AJOVY (fremanezumab-vfrm) is administered subcutaneously at a dose of 675 mg once every 3 months (quarterly) or 225 mg once monthly. The injection volume is 1.5 mL for the 225 mg dose and 4.5 mL for the 675 mg dose, administered as three separate injections of 225 mg each.
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life is 31 days (range 23-37 days). This long half-life supports monthly subcutaneous dosing.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Renal excretion of intact antibody is minimal; metabolized via catabolism to peptides and amino acids. Approximately 100% of elimination is via intracellular degradation (proteolysis) and biliary excretion of metabolites, with negligible renal excretion.
Category C
Category C
CGRP Antagonist
CGRP Antagonist